000			01886 a2200541 4500
005			20250514025451.0
264		0	_c20020409
008			200204s 0 0 eng d
022			_a1526-8209
024	7		_a10.3816/CBC.2000.n.012 _2doi
040			_aNLM _beng _cNLM
100	1		_aNicholson, B P
245	0	0	_aPaclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. _h[electronic resource]
260			_bClinical breast cancer _cJul 2000
300			_a136-43; discussion 144 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntimetabolites, Antineoplastic _xadministration & dosage
650	0	4	_aAntineoplastic Agents, Phytogenic _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xblood
650	0	4	_aBone Neoplasms _xblood
650	0	4	_aBreast Neoplasms _xpathology
650	0	4	_aDisease Progression
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Monitoring
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aLeucovorin _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aProportional Hazards Models
650	0	4	_aSoft Tissue Neoplasms _xblood
650	0	4	_aSurvival Analysis
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aViscera
700	1		_aPaul, D M
700	1		_aHande, K R
700	1		_aShyr, Y
700	1		_aMeshad, M
700	1		_aCohen, A
700	1		_aJohnson, D H
773	0		_tClinical breast cancer _gvol. 1 _gno. 2 _gp. 136-43; discussion 144
856	4	0	_uhttps://doi.org/10.3816/CBC.2000.n.012 _zAvailable from publisher's website
999			_c11805656 _d11805656